Iron Man Meets Physical Therapy: The Atalante Exoskeleton Takes on ALS

By The Biomedical Observer

If you've ever watched a sci-fi movie and thought, "I wish we had those robotic exoskeletons that help people walk," I have good news: we do. They exist. They're in rehabilitation centers. And one of them - the Atalante exoskeleton - is being tested as a potential therapy for one of the most challenging neurodegenerative conditions known to medicine: amyotrophic lateral sclerosis, or ALS.

The EXALS trial (NCT06199284) is asking a genuinely hopeful question: can strapping patients into a self-balancing robot that replicates natural walking patterns help preserve function in people whose motor neurons are progressively dying? It sounds like the kind of thing a naive optimist would propose, except it's backed by serious neuroscience and is actually running at research centers.

Let's dive in.

ALS: The Cruel Reality

ALS, also known as Lou Gehrig's disease, is what happens when the motor neurons - the nerve cells that control voluntary muscle movement - decide to check out. Progressive weakness starts somewhere (often in the limbs, sometimes in the muscles controlling speech and swallowing) and spreads inexorably until patients can no longer walk, use their arms, speak, swallow, or eventually breathe.

The median survival after diagnosis is about 3-5 years. There's no cure. There are only a handful of approved medications that modestly slow progression. Physical therapy helps maintain function but doesn't stop the underlying disease.

So when someone proposes using a walking robot to help ALS patients, the immediate reaction might be: "What's the point? The disease will progress anyway." But here's where things get interesting.

The Brain Can Adapt - If You Give It Reason To

Researchers have used MRI gait motor imagery paradigms to study how ALS affects the brain networks involved in walking. What they found wasn't just deterioration - they found reorganization. Compensatory networks appear to take over some functions as primary motor pathways fail.

The hypothesis driving the EXALS trial is beautifully simple: by providing coherent proprioceptive input to sensorimotor integration areas through exoskeleton-assisted walking, you might be able to boost this compensatory network reorganization and help maintain function longer.

In other words: if you keep giving the brain appropriate walking signals - proper feedback from movement, normal gait patterns, the sensory experience of locomotion - you might help it adapt better to the neurodegeneration it's experiencing.

It's not curing ALS. It's teaching the remaining healthy circuits to pick up more slack.

Enter the Atalante: Not Your Grandfather's Walking Aid

The Atalante exoskeleton, developed by the French company Wandercraft, isn't just strapping motors to someone's legs. It's a fully self-balancing system - the only exoskeleton of its kind that enables walking without any crutches, walkers, or arm support.

Think about that for a second. Most rehabilitation exoskeletons still require patients to use crutches or hold onto parallel bars. The Atalante stands on its own - literally. Equipped with 12 actuated degrees of motion and advanced dynamic walking algorithms, it mimics human walking in ways that cruder systems cannot.

For ALS patients, this is particularly relevant. Upper body weakness is common in ALS, meaning that exoskeletons requiring arm support would exclude many patients or become unusable as the disease progresses. A hands-free system keeps the door open longer.

The device includes a powered ankle mechanism that enables complex ankle movements - essential for replicating natural gait. It can perform multidirectional movement, not just forward marching. It's been described as engineering the way humans actually walk, rather than engineering something functional and calling it "close enough."

The EXALS Trial: What They're Actually Measuring

The EXALS study is an interventional, monocentric, prospective, open trial comparing exoskeleton-assisted gait training to usual care in ALS patients. They're measuring:

• Safety: Does strapping ALS patients into a walking robot cause problems? This seems obvious but needs documentation.
• Participant experience: Do patients actually like it? Are they motivated to continue? Rehabilitation that feels good gets done; rehabilitation that feels like torture gets abandoned.
• Walking ability: Can the exoskeleton training translate to improved unassisted walking?
• Functional capacity: Overall physical function - can they do more daily activities?
• Other motor disability symptoms: The broader picture of motor function.

The study design emphasizes participant perception and involvement in decision-making, which matters in a condition where autonomy is progressively lost. Giving patients agency in their treatment is therapeutic in itself.

Real-World Use: Where Atalante Already Lives

The Atalante isn't an experimental prototype locked in a lab. It's already deployed in over 100 rehabilitation and research centers worldwide. By late 2023, 820 patients had undergone rehabilitation programs using the system, taking over 1 million steps per month.

The current patient population includes people with:
- Hemiplegia (one-sided paralysis from stroke) - the most common use
- Paraplegia (paralysis from spinal cord injury)
- Tetraplegia (paralysis affecting all four limbs)
- Multiple sclerosis

The FDA has cleared Atalante X for stroke rehabilitation, spinal cord injury (levels C4 to L5), and multiple sclerosis. The EXALS trial represents an expansion into neurodegenerative disease territory - testing whether benefits seen in sudden-onset conditions (like stroke) translate to progressive conditions (like ALS).

The Neuroscience Behind the Hope

Here's what makes this more than wishful thinking. When humans walk, we're not just activating leg muscles. We're engaging complex sensorimotor loops that involve the brain, spinal cord, proprioceptors in muscles and joints, and visual/vestibular systems. Walking is a whole-body conversation.

In ALS, parts of this conversation go silent as motor neurons die. But other parts might be able to take over - if they receive the right signals. The exoskeleton provides those signals: proper joint angles, appropriate timing, realistic loading patterns. It's essentially speaking the language of walking to whatever neural circuits remain intact.

Some rehabilitation specialists believe that intensive, proper gait training can strengthen alternative neural pathways. Whether this hypothesis holds true in ALS - a disease that progressively destroys the very neurons you're trying to recruit - is exactly what the EXALS trial will test.

Exclusion Criteria: Who Can't Use Atalante

Not everyone can strap into an exoskeleton. The EXALS trial excludes patients with:
- Pressure ulcers in areas that contact the device
- Severe spasticity (Ashworth scale greater than 3) in key muscle groups
- Uncontrolled clonus (rhythmic muscle spasms)
- Cardiac or respiratory contraindications to physical effort

These are reasonable safety boundaries. An exoskeleton applies forces to the body; you need intact skin, manageable muscle tone, and cardiorespiratory reserve to tolerate the training.

Looking Forward: Cautious Optimism

Let me be clear about what this trial cannot do: it cannot cure ALS. Nothing currently can. The disease will still progress. Motor neurons will still die.

But "cannot cure" is not the same as "cannot help." If exoskeleton training can preserve walking function for additional months, improve quality of life, increase independence, or simply provide a sense of progress and agency in a disease defined by progressive loss - that matters. It matters a lot.

The study also contributes scientific knowledge. Understanding whether this approach provides benefit informs the broader field of ALS rehabilitation. Even negative results (finding that exoskeletons don't help ALS patients) would be valuable information that prevents others from pursuing dead ends.

There's something powerful about seeing a patient with a progressive neurological disease strap into a walking robot and take steps. It's technology meeting compassion meeting the stubborn human refusal to accept decline without a fight.

Whether Atalante becomes part of standard ALS care remains to be determined. But the fact that we're asking the question - running rigorous trials, measuring outcomes, treating ALS patients as candidates for cutting-edge rehabilitation technology rather than just hospice care - represents progress worth celebrating.

---

References:

1. Louie DR, et al. Hands-free Atalante exoskeleton in post-stroke gait and balance rehabilitation: a safety study. J Neuroeng Rehabil. 2025;22:76. DOI: 10.1186/s12984-025-01621-z

2. Wandercraft. Use of Atalante Self-balancing Exoskeleton in Neurological Rehabilitation: Insights from Real-world Data Across Europe and the United States. Arch Phys Med Rehabil. 2025. DOI: 10.1016/j.apmr.2025.01.013

3. Baunsgaard CB, et al. Evaluation of safety and performance of the self-balancing walking system Atalante in patients with complete motor spinal cord injury. Spinal Cord Ser Cases. 2021;7:71. DOI: 10.1038/s41394-021-00432-5

   

4. Clinical trial registration: NCT06199284

---

Disclaimer: This blog post is for informational purposes only and does not constitute medical advice. Clinical trials are ongoing research studies - consult with healthcare providers for medical decisions. The views expressed are those of the author and do not represent endorsement of any specific products or treatments. Images and graphics are for illustrative purposes only and do not depict actual medical devices, procedures, mechanisms, or research findings from the referenced studies.